StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Standpoint Research Downgrades Biogen (BIIB) to Hold
August 2, 2016 3:31 PM
Standpoint Research downgraded Biogen (NASDAQ: BIIB) from ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Downgrades
Next Articles
Biogen (BIIB) Could Be Worth $375-475/Share in a Takeover - RBC Capital's Yee
August 2, 2016 3:41 PM
Biogen (BIIB) Draws Takeover Interest from Allergan (AGN), Merck (MRK) - DJ
August 2, 2016 2:43 PM